The Antisense Oligonucleotide Therapeutics (ASO) Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Tremendous Research Efforts to Drive Market Growth Further
Due to the absence of clinical efficacy even at large ASO doses, interest in antisense oligonucleotide-based medication discovery and development had previously declined. However, tremendous research efforts were undertaken at the chemistry and biology interface to enhance the biophysical and biological characteristics of the ASOs. Due to their improved in vivo efficacy and low off-target effects, several ASO-based medicines have received FDA and EMA approval. Medical and biological sciences are now more motivated than ever to use various classes of ASOs to cure uncommon and hereditary disorders that were previously thought to be untreatable by traditional small-molecule-based therapeutics. This is due to the discovery of new molecular targets. In order to expand their therapeutic application based on patient history and clinical outcome, various classes of ASOs are being successfully evaluated to treat the same diseases.
Several Potential Applications of ASO to Boost Market Growth
The present antisense drugs, which are still in the clinical development stage, specifically target certain tissues on a systemic and local level. The enhanced oligonucleotide chemistry increases the potency, safety, and tissue dispersion of the antisense drugs, further enhancing their properties. The mechanism of binding to RNA to decrease their activity both with & without RNA degradation has been improved by the development of oligonucleotide designs. Recent studies have shown that antisense oligonucleotides can also be used to either overexpress or decrease the creation of proteins. The effectiveness of new compounds in clinical trials will be the defining factor of how antisense technology is used in the future.
What Questions Should You Ask before Buying a Market Research Report?
• How is the antisense oligonucleotide therapeutics market evolving?
• What is driving and restraining the antisense oligonucleotide therapeutics market?
• How will each antisense oligonucleotide therapeutics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each antisense oligonucleotide therapeutics submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading antisense oligonucleotide therapeutics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the antisense oligonucleotide therapeutics projects for these leading companies?
• How will the industry evolve during the period between 2022 and 2032? What are the implications of
antisense oligonucleotide therapeutics projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the antisense oligonucleotide therapeutics market?
• Where is the antisense oligonucleotide therapeutics market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the antisense oligonucleotide therapeutics market today, and over the next 10 years:
• Our 297-page report provides 117 tables and 152 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the antisense oligonucleotide therapeutics market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Therapeutic Area
• Genetic Disorders
• Neurological Disorders
• Oncological Disorders
• Metabolic Disorders
• Ophthalmic Disorders
• Others
Type
• Ribozyme
• DNAzyme
• Anti-Gene
• Other Types
Route of Administration
• Pulmonary Delivery
• Intravenous Injections
• Intradermal Injections
• Intraperitoneal Injections
• Topical Delivery
• Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:
North America
• U.S.
• Canada
Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe
Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
MEA
• GCC
• South Africa
• Rest of MEA
Need industry data? Please contact us today.
The report also includes profiles and for some of the leading companies in the Antisense Oligonucleotide Therapeutics Market, 2022 to 2032, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• Alnylam Pharmaceuticals, Inc.
• Antisense Therapeutics Limited
• Arrowhead Pharmaceuticals, Inc.
• Biogen
• Bio-Path Holdings
• GSK
• Geron Corporation (Geron)
• Ionis Pharmaceuticals, Inc.
• ProQR Therapeutics
• Sarepta Therapeutics
• Sterna Biologicals
Overall world revenue for Antisense Oligonucleotide Therapeutics Market, 2022 to 2032 in terms of value the market will surpass US$19 billion in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Antisense Oligonucleotide Therapeutics Market, 2022 to 2032 report help you?
In summary, our 280+ page report provides you with the following knowledge:
• Revenue forecasts to 2032 for Antisense Oligonucleotide Therapeutics Market, 2022 to 2032 Market, with forecasts for therapeutic area, type, and route of administration, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2032 for five regional and 20 key national markets – See forecasts for the Antisense Oligonucleotide Therapeutics Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 11 of the major companies involved in the Antisense Oligonucleotide Therapeutics Market, 2022 to 2032.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Antisense Oligonucleotide Therapeutics Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Antisense Oligonucleotide (ASO) Therapeutics Market Report 2022-2032: Forecasts by Therapeutic Area (Genetic Disorders, Neurological Disorders, Oncological Disorders, Metabolic Disorders, Ophthalmic Disorders, Others), by Type (Ribozyme, DNAzyme, Anti-Gene, Others), by Route of Administration (Pulmonary Delivery, Intravenous Injections, Intradermal Injections, Intraperitoneal Injections, Topical Delivery, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1. Report Overview
1.1 Objectives of the Study
1.2 Introduction to Antisense Oligonucleotide Therapeutics Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered By This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Worldwide Cancer Burden to Fuel Market Growth
3.2.1.2 Advances in Drug Delivery
3.2.2 Market Restraining Factors
3.2.2.1 Competition from Generics Likely to Hamper Market Growth
3.2.2.2 Distribution of Antisense Drugs to Distant Tumors
3.2.3 Market Opportunities
3.2.3.1 Investments by Major Players to Boost Market Growth
3.2.3.2 Emerging Markets
3.2.3.3 Development of Better Diagnostic Methods
3.2.3.4 Acquisitions and Partnerships
3.2.3.5 Pipeline Drugs Anticipated to Offer Lucrative Growth Opportunities
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
4 Antisense Oligonucleotide Therapeutics Products and Technology Overview
4.1 Introduction to Nucleic Acid Technologies
4.2 Genetic Variation and Analysis
4.2.1 Sequencing Technologies
4.2.2 Sanger Sequencing
4.3 Next-generation Sequencing
4.3.1 DNA Write (Synthesis) Technologies
4.4 PCR-Based Approaches
4.5 Solid-Phase-Based Approaches
4.5.1 Microfluidic Technologies
4.5.2 DNA Microarrays
4.6 Gene Editing Technologies
4.7 CRISPR Enzyme Technologies
4.8 Gene Editing Delivery Technologies
4.9 Viral Delivery Technologies
4.9.1 Non-Viral Delivery Technologies
5 DNA Read, Write and Edit Initiatives
5.1 Initiatives
5.2 American Gut Consortium
5.2.1 BabySeq
5.2.2 Blood Profiling Atlas
5.2.3 Cancer-ID
5.2.4 Cancer Moon Shots Program
5.2.5 China Precision Medicine Initiative
5.2.6 Clinical Genome Resource
5.2.7 Epigenetics for Females Personalized Cancer Care
5.2.8 France Genomic Medicine Plan
5.2.9 Friends of Cancer Research Project
5.3 Gene Therapy Initiative
5.3.1 Immunomonitor Consortium
5.3.2 Integration of Imaging and Fluid-based Tumor Monitoring in Cancer Therapy Program
5.3.3 Laboratory for Genomics Research
5.3.4 Lung Cancer Master Protocol Project
5.3.5 Matchmaker Exchange
5.3.6 Medical Genome Initiative
5.3.7 Million Veteran Program
5.3.8 Molecular Integration in Neurological Diagnosis
5.3.9 MedSeq
5.4 National Microbiome Initiative
5.4.1 Next-generation Single Cell Analysis Program
5.4.2 Precision Medicine Initiative
5.4.3 Prospective Registry of Multiple Testing
5.4.4 Quality Assurance Initiative Pathology Project
5.4.5 Somatic Cell Genome Editing Program
5.4.6 Telomere-to-Telomere Consortium
5.4.7 Trans Omics for Precision Medicine Initiative
5.4.8 Population Sequencing Programs
6 Antisense Oligonucleotide Therapeutics Market Analysis by Therapeutic Area
6.1 Key Findings
6.2 Therapeutic Area Segment: Market Attractiveness Index
6.3 Antisense Oligonucleotide Therapeutics Market Size Estimation and Forecast by Therapeutic Area
6.4 Genetic Disorders
6.4.1 Market Forecast by Region, 2022-2032 (US$ bn)
6.4.2 Market Share by Region, 2022 & 2032 (%)
6.5 Neurological Disorders
6.5.1 Market Forecast by Region, 2022-2032 (US$ bn)
6.5.2 Market Share by Region, 2022 & 2032 (%)
6.6 Oncological Disorders
6.6.1 Market Forecast by Region, 2022-2032 (US$ bn)
6.6.2 Market Share by Region, 2022 & 2032 (%)
6.7 Metabolic Disorders
6.7.1 Market Forecast by Region, 2022-2032 (US$ bn)
6.7.2 Market Share by Region, 2022 & 2032 (%)
6.8 Ophthalmic Disorders
6.8.1 Market Forecast by Region, 2022-2032 (US$ bn)
6.8.2 Market Share by Region, 2022 & 2032 (%)
6.9 Others
6.9.1 Market Forecast by Region, 2022-2032 (US$ bn)
6.9.2 Market Share by Region, 2022 & 2032 (%)
7 Antisense Oligonucleotide Therapeutics Market Analysis by Type
7.1 Key Findings
7.2 Type Segment: Market Attractiveness Index
7.3 Antisense Oligonucleotide Therapeutics Market Size Estimation and Forecast by Type
7.4 Ribozyme
7.4.1 Market Forecast by Region, 2022-2032 (US$ bn)
7.4.2 Market Share by Region, 2022 & 2032 (%)
7.5 DNAzyme
7.5.1 Market Forecast by Region, 2022-2032 (US$ bn)
7.5.2 Market Share by Region, 2022 & 2032 (%)
7.6 Anti-Gene
7.6.1 Market Forecast by Region, 2022-2032 (US$ bn)
7.6.2 Market Share by Region, 2022 & 2032 (%)
7.7 Other Types
7.7.1 Market Forecast by Region, 2022-2032 (US$ bn)
7.7.2 Market Share by Region, 2022 & 2032 (%)
8 Antisense Oligonucleotide Therapeutics Market Analysis by Route of Administration
8.1 Key Findings
8.2 Route of Administration Segment: Market Attractiveness Index
8.3 Antisense Oligonucleotide Therapeutics Market Size Estimation and Forecast by Route of Administration
8.4 Pulmonary Delivery
8.4.1 Market Forecast by Region, 2022-2032 (US$ bn)
8.4.2 Market Share by Region, 2022 & 2032 (%)
8.5 Intravenous Injections
8.5.1 Market Forecast by Region, 2022-2032 (US$ bn)
8.5.2 Market Share by Region, 2022 & 2032 (%)
8.6 Intradermal Injections
8.6.1 Market Forecast by Region, 2022-2032 (US$ bn)
8.6.2 Market Share by Region, 2022 & 2032 (%)
8.7 Intraperitoneal Injections
8.7.1 Market Forecast by Region, 2022-2032 (US$ bn)
8.7.2 Market Share by Region, 2022 & 2032 (%)
8.8 Topical Delivery
8.8.1 Market Forecast by Region, 2022-2032 (US$ bn)
8.8.2 Market Share by Region, 2022 & 2032 (%)
8.9 Others
8.9.1 Market Forecast by Region, 2022-2032 (US$ bn)
8.9.2 Market Share by Region, 2022 & 2032 (%)
9 Antisense Oligonucleotide Therapeutics Market Analysis by Region
9.1 Key Findings
9.2 Regional Market Size Estimation and Forecast
10 North America Antisense Oligonucleotide Therapeutics Market Analysis
10.1 Key Findings
10.2 North America Antisense Oligonucleotide Therapeutics Market Attractiveness Index
10.3 Market Size by Country, 2022, 2027 & 2032 (US$ bn)
10.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ bn)
10.5 Market Size Estimation and Forecast by Therapeutic Area, 2022-2032 (US$ bn)
10.6 Market Size Estimation and Forecast by Type, 2022-2032 (US$ bn)
10.7 Market Size Estimation and Forecast by Route of Administration, 2022-2032 (US$ bn)
10.8 U.S.
10.9 Canada
11 Europe Antisense Oligonucleotide Therapeutics Market Analysis
11.1 Key Findings
11.2 Europe Antisense Oligonucleotide Therapeutics Market Attractiveness Index
11.3 Market Size by Country, 2022, 2027 & 2032 (US$ bn)
11.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ bn)
11.5 Market Size Estimation and Forecast by Therapeutic Area, 2022-2032 (US$ bn)
11.6 Market Size Estimation and Forecast by Type, 2022-2032 (US$ bn)
11.7 Market Size Estimation and Forecast by Route of Administration, 2022-2032 (US$ bn)
11.8 Germany
11.9 UK
11.10 France
11.11 Italy
11.12 Spain
11.13 Rest of Europe
12 Asia Pacific Antisense Oligonucleotide Therapeutics Market Analysis
12.1 Key Findings
12.2 Asia Pacific Antisense Oligonucleotide Therapeutics Market Attractiveness Index
12.3 Market Size by Country, 2022, 2027 & 2032 (US$ bn)
12.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ bn)
12.5 Market Size Estimation and Forecast by Therapeutic Area, 2022-2032 (US$ bn)
12.6 Market Size Estimation and Forecast by Type, 2022-2032 (US$ bn)
12.7 Market Size Estimation and Forecast by Route of Administration, 2022-2032 (US$ bn)
12.8 Japan
12.9 China
12.10 India
12.11 Australia
12.12 South Korea
12.13 Rest of Asia Pacific
13 Latin America Antisense Oligonucleotide Therapeutics Market Analysis
13.1 Key Findings
13.2 Latin America Antisense Oligonucleotide Therapeutics Market Attractiveness Index
13.3 Market Size by Country, 2022, 2027 & 2032 (US$ bn)
13.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ bn)
13.5 Market Size Estimation and Forecast by Therapeutic Area, 2022-2032 (US$ bn)
13.6 Market Size Estimation and Forecast by Type, 2022-2032 (US$ bn)
13.7 Market Size Estimation and Forecast by Route of Administration, 2022-2032 (US$ bn)
13.8 Brazil
13.9 Mexico
13.10 Rest of Latin America
14 MEA Antisense Oligonucleotide Therapeutics Market Analysis
14.1 Key Findings
14.2 MEA Antisense Oligonucleotide Therapeutics Market Attractiveness Index
14.3 Market Size by Country, 2022, 2027 & 2032 (US$ bn)
14.4 Market Size Estimation and Forecast by Country, 2022-2032 (US$ bn)
14.5 Market Size Estimation and Forecast by Therapeutic Area, 2022-2032 (US$ bn)
14.6 Market Size Estimation and Forecast by Type, 2022-2032 (US$ bn)
14.7 Market Size Estimation and Forecast by Route of Administration, 2022-2032 (US$ bn)
14.8 GCC
14.9 South Africa
14.10 Rest of MEA
15 Company Profiles
15.1 Biogen
15.1.1 Company Snapshot
15.1.2 Company Overview
15.1.3 Financial Analysis
15.1.3.1 Net Revenue, 2017-2021
15.1.3.2 Gross Profit, 2017-2021
15.1.3.3 R&D, 2017-2021
15.1.4 Product Benchmarking
15.1.5 Strategic Outlook
15.2 Bio-Path Holdings
15.2.1 Company Snapshot
15.2.2 Company Overview
15.2.3 Product Benchmarking
15.2.4 Strategic Outlook
15.3 Ionis Pharmaceuticals, Inc.
15.3.1 Company Snapshot
15.3.2 Company Overview
15.3.3 Financial Analysis
15.3.3.1 Net Revenue, 2017-2021
15.3.3.2 Gross Profit, 2017-2021
15.3.3.3 R&D, 2017-2021
15.3.4 Product Benchmarking
15.3.5 Strategic Outlook
15.4 ProQR Therapeutics
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Product Benchmarking
15.4.4 Strategic Outlook
15.5 Sarepta Therapeutics
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Financial Analysis
15.5.3.1 Net Revenue, 2017-2021
15.5.3.2 Gross Profit, 2017-2021
15.5.3.3 R&D, 2017-2021
15.5.4 Product Benchmarking
15.5.5 Strategic Outlook
15.6 Alnylam Pharmaceuticals, Inc.
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Financial Analysis
15.6.3.1 Net Revenue, 2017-2021
15.6.3.2 Gross Profit, 2017-2021
15.6.3.3 R&D, 2017-2021
15.6.4 Product Benchmarking
15.6.5 Strategic Outlook
15.7 Arrowhead Pharmaceuticals, Inc.
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Financial Analysis
15.7.3.1 Net Revenue, 2017-2021
15.7.3.2 Gross Profit, 2017-2021
15.7.3.3 R&D, 2017-2021
15.7.4 Product Benchmarking
15.7.5 Strategic Outlook
15.8 GSK
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Financial Analysis
15.8.3.1 Net Revenue, 2017-2021
15.8.3.2 Gross Profit, 2017-2021
15.8.3.3 R&D, 2017-2021
15.8.4 Product Benchmarking
15.9 Geron Corporation (Geron)
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Financial Analysis
15.9.3.1 Net Revenue, 2017-2021
15.9.3.2 R&D, 2017-2021
15.9.4 Product Benchmarking
15.10 Antisense Therapeutics Limited
15.10.1 Company Snapshot
15.10.2 Company Overview
15.10.3 Financial Analysis
15.10.3.1 Net Revenue, 2017-2021
15.10.3.2 R&D, 2017-2021
15.10.4 Product Benchmarking
15.10.5 Strategic Outlook
15.11 Sterna Biologicals
15.11.1 Company Snapshot
15.11.2 Company Overview
15.11.3 Product Benchmarking
15.11.4 Strategic Outlook
16 Conclusion and Recommendations
16.1 Concluding Remarks from Visiongain
16.2 Recommendations for Market Players
List of Tables
Table 1 Antisense Oligonucleotide Therapeutics Market Snapshot, 2022 & 2032 (US$ billion, CAGR %)
Table 2 Approval
Table 3 Chemical Building Blocks of DNA
Table 4 DNA Translation and Transcription
Table 5 Long-range DNA Structure
Table 6 Genetic Variant Types
Table 7 DNA Read, Write and Edit Technology Overview
Table 8 Sequencing Technology Development, 1990-2020
Table 9 Cost to Sequence a Single Human Genome, 2001-2019($)
Table 10 Sequencing Technology Summary
Table 11 Sanger Sequencing Summary
Table 12 Sanger Sequencing Improvements
Table 13 Advanced Sequencing Technologies
Table 14 Roche Next-generation Sequencing Workflow
Table 15 Illumina Next-generation Sequencing Workflow
Table 16 Comparison of Gene Synthesis Technologies
Table 17 Importance of Microfluidics Technologies in Read and Write Applications
Table 18 Gene Editing Therapeutic Interventions
Table 19 Gene Editing Technology Approaches
Table 20 Major Gene Editing Technologies
Table 21 Comparison of CRISPR Enzyme Technologies
Table 22 Delivery Vector Technical Hurdles
Table 23 Comparison of Viral Vector Types
Table 24 Non-Viral Delivery Methods
Table 25 DNA Read, Write and Edit: R&D Programs
Table 26 Population Sequencing Projects
Table 27 Antisense Oligonucleotide Therapeutics Market Forecast by Therapeutic Area, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 28 Genetic Disorders Segment Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 29 Neurological Disorders Segment Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 30 Oncological Disorders Segment Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 31 Metabolic Disorders Segment Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 32 Ophthalmic Disorders Segment Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 33 Other Disorders Segment Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 34 North America Antisense Oligonucleotide Therapeutics Market Forecast by Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 35 Ribozyme Segment Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 36 DNAzyme Segment Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 37 Anti-Gene Segment Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 38 Others Segment Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 39 Antisense Oligonucleotide Therapeutics Market Forecast by Route of Administration, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 40 Pulmonary Delivery Segment Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 41 Intravenous Injections Segment Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 42 Intradermal Injections Segment Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 43 Intraperitoneal Injections Segment Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 44 Topical Delivery Segment Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 45 Others Segment Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 46 Antisense Oligonucleotide Therapeutics Market Forecast by Region, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 47 North America Antisense Oligonucleotide Therapeutics Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 48 North America Antisense Oligonucleotide Therapeutics Market Forecast by Therapeutic Area, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 49 North America Antisense Oligonucleotide Therapeutics Market Forecast by Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 50 North America Antisense Oligonucleotide Therapeutics Market Forecast by Route of Administration, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 51 U.S. Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 52 Canada Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 53 Europe Antisense Oligonucleotide Therapeutics Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 54 Europe Antisense Oligonucleotide Therapeutics Market Forecast by Therapeutic Area, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 55 Europe Antisense Oligonucleotide Therapeutics Market Forecast by Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 56 Europe Antisense Oligonucleotide Therapeutics Market Forecast by Route of Administration, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 57 Germany Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 58 UK Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 59 France Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 60 Italy Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 61 Spain Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 62 Rest of Europe Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 63 Asia Pacific Antisense Oligonucleotide Therapeutics Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 64 Asia Pacific Antisense Oligonucleotide Therapeutics Market Forecast by Therapeutic Area, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 65 Asia Pacific Antisense Oligonucleotide Therapeutics Market Forecast by Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 66 Asia Pacific Antisense Oligonucleotide Therapeutics Market Forecast by Route of Administration, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 67 Japan Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 68 China Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 69 India Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 70 Australia Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 71 South Korea Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 72 Rest of Asia Pacific Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 73 Latin America Antisense Oligonucleotide Therapeutics Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 74 Latin America Antisense Oligonucleotide Therapeutics Market Forecast by Therapeutic Area, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 75 Latin America Antisense Oligonucleotide Therapeutics Market Forecast by Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 76 Latin America Antisense Oligonucleotide Therapeutics Market Forecast by Route of Administration, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 77 Brazil Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 78 Mexico Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 79 Rest of Latin America Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 80 MEA Antisense Oligonucleotide Therapeutics Market Forecast by Country, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 81 MEA Antisense Oligonucleotide Therapeutics Market Forecast by Therapeutic Area, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 82 MEA Antisense Oligonucleotide Therapeutics Market Forecast by Type, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 83 MEA Antisense Oligonucleotide Therapeutics Market Forecast by Route of Administration, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 84 GCC Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 85 South Africa Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 86 Rest of MEA Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ bn, AGR%, CAGR%)
Table 87 Biogen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 Biogen: Product Benchmarking
Table 89 Biogen: Strategic Outlook
Table 90 Bio-Path Holdings: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 Bio-Path Holdings: Product Benchmarking
Table 92 Bio-Path Holdings: Strategic Outlook
Table 93 Ionis Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 Ionis Pharmaceuticals, Inc.: Product Benchmarking
Table 95 Ionis Pharmaceuticals, Inc.: Strategic Outlook
Table 96 ProQR Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 ProQR Therapeutics: Product Benchmarking
Table 98 ProQR Therapeutics: Strategic Outlook
Table 99 Sarepta Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 Sarepta Therapeutics: Product Benchmarking
Table 101 Sarepta Therapeutics: Strategic Outlook
Table 102 Alnylam Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Alnylam Pharmaceuticals, Inc.: Product Benchmarking
Table 104 Alnylam Pharmaceuticals, Inc.: Strategic Outlook
Table 105 Arrowhead Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 106 Arrowhead Pharmaceuticals, Inc.: Product Benchmarking
Table 107 Arrowhead Pharmaceuticals, Inc.: Strategic Outlook
Table 108 GSK: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 109 GSK: Product Benchmarking
Table 110 Geron Corporation (Geron): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 111 Geron Corporation (Geron): Product Benchmarking
Table 112 Antisense Therapeutics Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Antisense Therapeutics Limited: Product Benchmarking
Table 114 Antisense Therapeutics Limited: Strategic Outlook
Table 115 Sterna Biologicals: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 116 Sterna Biologicals: Product Benchmarking
Table 117 Sterna Biologicals: Strategic Outlook
List of Figures
Figure 1 Antisense Oligonucleotide Therapeutics Market Segmentation
Figure 2 Antisense Oligonucleotide Therapeutics Market by Therapeutic Area: Market Attractiveness Index
Figure 3 Antisense Oligonucleotide Therapeutics Market by Type: Market Attractiveness Index
Figure 4 Antisense Oligonucleotide Therapeutics Market by Route of Administration: Market Attractiveness Index
Figure 5 Antisense Oligonucleotide Therapeutics Market Attractiveness Index by Region
Figure 6 Antisense Oligonucleotide Therapeutics Market: Market Dynamics
Figure 7 COVID Impact Analysis: Antisense Oligonucleotide Therapeutics Market Recovery Scenarios
Figure 8 Antisense Oligonucleotide Therapeutics Market by Region, 2022-2032 (US$ bn, AGR %): “V” Shaped Recovery
Figure 9 Antisense Oligonucleotide Therapeutics Market by Region, 2022-2032 (US$ bn, AGR %): “U” Shaped Recovery
Figure 10 Antisense Oligonucleotide Therapeutics Market by Region, 2022-2032 (US$ bn, AGR %): “W” Shaped Recovery
Figure 11 Antisense Oligonucleotide Therapeutics Market by Region, 2022-2032 (US$ bn, AGR %): “L” Shaped Recovery
Figure 12 Antisense Oligonucleotide Therapeutics Market: Porter’s Five Forces Analysis
Figure 13 Antisense Oligonucleotide Therapeutics Market: PEST Analysis
Figure 14 Central Dogma of Molecular Biology
Figure 15 Schematic of Conventional DNA Synthesis Technologies
Figure 16 Microarrays in DNA Synthesis
Figure 17 Antisense Oligonucleotide Therapeutics Market Attractiveness Index by Therapeutic Area
Figure 18 Antisense Oligonucleotide Therapeutics Market Forecast by Therapeutic Area, 2022-2032 (US$ billion)
Figure 19 Antisense Oligonucleotide Therapeutics Market Share Forecast by Therapeutic Area, 2022, 2027, 2032 (%)
Figure 20 Genetic Disorders Market Forecast by Region, 2022-2032 (US$ billion)
Figure 21 Genetic Disorders Market Share Forecast by Region, 2022 & 2032 (%)
Figure 22 Neurological Disorders Market Forecast by Region, 2022-2032 (US$ billion)
Figure 23 Neurological Disorders Market Share Forecast by Region, 2022 & 2032 (%)
Figure 24 Oncological Disorders Market Forecast by Region, 2022-2032 (US$ billion)
Figure 25 Oncological Disorders Market Share Forecast by Region, 2022 & 2032 (%)
Figure 26 Metabolic Disorders Market Forecast by Region, 2022-2032 (US$ billion)
Figure 27 Metabolic Disorders Market Share Forecast by Region, 2022 & 2032 (%)
Figure 28 Ophthalmic Disorders Market Forecast by Region, 2022-2032 (US$ billion)
Figure 29 Ophthalmic Disorders Market Share Forecast by Region, 2022 & 2032 (%)
Figure 30 Others Market Forecast by Region, 2022-2032 (US$ billion)
Figure 31 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 32 Antisense Oligonucleotide Therapeutics Market Attractiveness Index by Type
Figure 33 Antisense Oligonucleotide Therapeutics Market Forecast by Type, 2022-2032 (US$ billion)
Figure 34 Antisense Oligonucleotide Therapeutics Market Share Forecast by Type, 2022, 2027, 2032 (%)
Figure 35 Ribozyme Market Forecast by Region, 2022-2032 (US$ billion)
Figure 36 Ribozyme Market Share Forecast by Region, 2022 & 2032 (%)
Figure 37 DNAzyme Market Forecast by Region, 2022-2032 (US$ billion)
Figure 38 DNAzyme Market Share Forecast by Region, 2022 & 2032 (%)
Figure 39 Anti-Gene Market Forecast by Region, 2022-2032 (US$ billion)
Figure 40 Anti-Gene Market Share Forecast by Region, 2022 & 2032 (%)
Figure 41 Other Types Market Forecast by Region, 2022-2032 (US$ billion)
Figure 42 Other Types Market Share Forecast by Region, 2022 & 2032 (%)
Figure 43 Antisense Oligonucleotide Therapeutics Market Attractiveness Index by Route of Administration
Figure 44 Antisense Oligonucleotide Therapeutics Market Forecast by Route of Administration, 2022-2032 (US$ billion)
Figure 45 Antisense Oligonucleotide Therapeutics Market Share Forecast by Route of Administration, 2022, 2027, 2032 (%)
Figure 46 Pulmonary Delivery Market Forecast by Region, 2022-2032 (US$ billion)
Figure 47 Pulmonary Delivery Market Share Forecast by Region, 2022 & 2032 (%)
Figure 48 Intravenous Injections Market Forecast by Region, 2022-2032 (US$ billion)
Figure 49 Intravenous Injections Market Share Forecast by Region, 2022 & 2032 (%)
Figure 50 Intradermal Injections Market Forecast by Region, 2022-2032 (US$ billion)
Figure 51 Intradermal Injections Market Share Forecast by Region, 2022 & 2032 (%)
Figure 52 Intraperitoneal Injections Market Forecast by Region, 2022-2032 (US$ billion)
Figure 53 Intraperitoneal Injections Market Share Forecast by Region, 2022 & 2032 (%)
Figure 54 Topical Delivery Market Forecast by Region, 2022-2032 (US$ billion)
Figure 55 Topical Delivery Market Share Forecast by Region, 2022 & 2032 (%)
Figure 56 Others Market Forecast by Region, 2022-2032 (US$ billion)
Figure 57 Others Market Share Forecast by Region, 2022 & 2032 (%)
Figure 58 Antisense Oligonucleotide Therapeutics Market Forecast by Region 2022, 2027, 2032 (Revenue, CAGR%)
Figure 59 Antisense Oligonucleotide Therapeutics Market Share Forecast by Region 2022, 2027, 2032(%)
Figure 60 Antisense Oligonucleotide Therapeutics Market by Region, 2022-2032 (US$ bn)
Figure 61 North America Antisense Oligonucleotide Therapeutics Market Attractiveness Index
Figure 62 North America Antisense Oligonucleotide Therapeutics Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 63 North America Antisense Oligonucleotide Therapeutics Market Forecast by Country, 2022-2032 (US$ billion)
Figure 64 North America Antisense Oligonucleotide Therapeutics Market Share Forecast by Country, 2022 & 2032 (%)
Figure 65 North America Antisense Oligonucleotide Therapeutics Market Forecast by Therapeutic Area, 2022-2032 (US$ billion)
Figure 66 North America Antisense Oligonucleotide Therapeutics Market Share Forecast by Therapeutic Area, 2022 & 2032 (%)
Figure 67 North America Antisense Oligonucleotide Therapeutics Market Forecast by Type, 2022-2032 (US$ billion)
Figure 68 North America Antisense Oligonucleotide Therapeutics Market Share Forecast by Type, 2022 & 2032 (%)
Figure 69 North America Antisense Oligonucleotide Therapeutics Market Forecast by Route of Administration, 2022-2032 (US$ billion)
Figure 70 North America Antisense Oligonucleotide Therapeutics Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 71 U.S. Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 72 Canada Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 73 Europe Antisense Oligonucleotide Therapeutics Market Attractiveness Index
Figure 74 Europe Antisense Oligonucleotide Therapeutics Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 75 Europe Antisense Oligonucleotide Therapeutics Market Forecast by Country, 2022-2032 (US$ billion)
Figure 76 Europe Antisense Oligonucleotide Therapeutics Market Share Forecast by Country, 2022 & 2032 (%)
Figure 77 Europe Antisense Oligonucleotide Therapeutics Market Forecast by Therapeutic Area, 2022-2032 (US$ billion)
Figure 78 Europe Antisense Oligonucleotide Therapeutics Market Share Forecast by Therapeutic Area, 2022 & 2032 (%)
Figure 79 Europe Antisense Oligonucleotide Therapeutics Market Forecast by Type, 2022-2032 (US$ billion)
Figure 80 Europe Antisense Oligonucleotide Therapeutics Market Share Forecast by Type, 2022 & 2032 (%)
Figure 81 Europe Antisense Oligonucleotide Therapeutics Market Forecast by Route of Administration, 2022-2032 (US$ billion)
Figure 82 Europe Antisense Oligonucleotide Therapeutics Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 83 Germany Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 84 UK Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 85 France Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 86 Italy Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 87 Spain Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 88 Rest of Europe Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 89 Asia Pacific Antisense Oligonucleotide Therapeutics Market Attractiveness Index
Figure 90 Asia Pacific Antisense Oligonucleotide Therapeutics Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 91 Asia Pacific Antisense Oligonucleotide Therapeutics Market Forecast by Country, 2022-2032 (US$ billion)
Figure 92 Asia Pacific Antisense Oligonucleotide Therapeutics Market Share Forecast by Country, 2022 & 2032 (%)
Figure 93 Asia Pacific Antisense Oligonucleotide Therapeutics Market Forecast by Therapeutic Area, 2022-2032 (US$ billion)
Figure 94 Asia Pacific Antisense Oligonucleotide Therapeutics Market Share Forecast by Therapeutic Area, 2022 & 2032 (%)
Figure 95 Asia Pacific Antisense Oligonucleotide Therapeutics Market Forecast by Type, 2022-2032 (US$ billion)
Figure 96 Asia Pacific Antisense Oligonucleotide Therapeutics Market Share Forecast by Type, 2022 & 2032 (%)
Figure 97 Asia Pacific Antisense Oligonucleotide Therapeutics Market Forecast by Route of Administration, 2022-2032 (US$ billion)
Figure 98 Asia Pacific Antisense Oligonucleotide Therapeutics Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 99 Japan Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 100 China Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 101 India Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 102 Australia Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 103 South Korea Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 104 Rest of Asia Pacific Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 105 Latin America Antisense Oligonucleotide Therapeutics Market Attractiveness Index
Figure 106 Latin America Antisense Oligonucleotide Therapeutics Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 107 Latin America Antisense Oligonucleotide Therapeutics Market Forecast by Country, 2022-2032 (US$ billion)
Figure 108 Latin America Antisense Oligonucleotide Therapeutics Market Share Forecast by Country, 2022 & 2032 (%)
Figure 109 Latin America Antisense Oligonucleotide Therapeutics Market Forecast by Therapeutic Area, 2022-2032 (US$ billion)
Figure 110 Latin America Antisense Oligonucleotide Therapeutics Market Share Forecast by Therapeutic Area, 2022 & 2032 (%)
Figure 111 Latin America Antisense Oligonucleotide Therapeutics Market Forecast by Type, 2022-2032 (US$ billion)
Figure 112 Latin America Antisense Oligonucleotide Therapeutics Market Share Forecast by Type, 2022 & 2032 (%)
Figure 113 Latin America Antisense Oligonucleotide Therapeutics Market Forecast by Route of Administration, 2022-2032 (US$ billion)
Figure 114 Latin America Antisense Oligonucleotide Therapeutics Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 115 Brazil Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 116 Mexico Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 117 Rest of Latin America Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 118 MEA Antisense Oligonucleotide Therapeutics Market Attractiveness Index
Figure 119 MEA Antisense Oligonucleotide Therapeutics Market by Region, 2022, 2027 & 2032 (US$ billion)
Figure 120 MEA Antisense Oligonucleotide Therapeutics Market Forecast by Country, 2022-2032 (US$ billion)
Figure 121 MEA Antisense Oligonucleotide Therapeutics Market Share Forecast by Country, 2022 & 2032 (%)
Figure 122 MEA Antisense Oligonucleotide Therapeutics Market Forecast by Therapeutic Area, 2022-2032 (US$ billion)
Figure 123 MEA Antisense Oligonucleotide Therapeutics Market Share Forecast by Therapeutic Area, 2022 & 2032 (%)
Figure 124 MEA Antisense Oligonucleotide Therapeutics Market Forecast by Type, 2022-2032 (US$ billion)
Figure 125 MEA Antisense Oligonucleotide Therapeutics Market Share Forecast by Type, 2022 & 2032 (%)
Figure 126 MEA Antisense Oligonucleotide Therapeutics Market Forecast by Route of Administration, 2022-2032 (US$ billion)
Figure 127 MEA Antisense Oligonucleotide Therapeutics Market Share Forecast by Route of Administration, 2022 & 2032 (%)
Figure 128 GCC Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 129 South Africa Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 130 Rest of MEA Antisense Oligonucleotide Therapeutics Market Forecast, 2022-2032 (US$ billion, AGR %)
Figure 131 Biogen: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 132 Biogen: Gross Profit, 2017-2021 (US$ million, AGR%)
Figure 133 Biogen: R&D, 2017-2021 (US$ million, AGR%)
Figure 134 Ionis Pharmaceuticals, Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 135 Ionis Pharmaceuticals, Inc.: Gross Profit, 2017-2021 (US$ million, AGR%)
Figure 136 Ionis Pharmaceuticals, Inc.: R&D, 2017-2021 (US$ million, AGR%)
Figure 137 Sarepta Therapeutics: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 138 Sarepta Therapeutics: Gross Profit, 2017-2021 (US$ million, AGR%)
Figure 139 Sarepta Therapeutics: R&D, 2017-2021 (US$ million, AGR%)
Figure 140 Alnylam Pharmaceuticals, Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 141 Alnylam Pharmaceuticals, Inc.: Gross Profit, 2017-2021 (US$ million, AGR%)
Figure 142 Alnylam Pharmaceuticals, Inc.: R&D, 2017-2021 (US$ million, AGR%)
Figure 143 Arrowhead Pharmaceuticals, Inc.: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 144 Arrowhead Pharmaceuticals, Inc.: Gross Profit, 2017-2021 (US$ million, AGR%)
Figure 145 Arrowhead Pharmaceuticals, Inc.: R&D, 2017-2021 (US$ million, AGR%)
Figure 146 GSK: Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 147 GSK: Gross Profit, 2017-2021 (US$ million, AGR%)
Figure 148 GSK: R&D, 2017-2021 (US$ million, AGR%)
Figure 149 Geron Corporation (Geron): Net Revenue, 2017-2021 (US$ million, AGR%)
Figure 150 Geron Corporation (Geron): R&D, 2017-2021 (US$ million, AGR%)
Figure 151 Antisense Therapeutics Limited: Net Revenue, 2017-2021 (US$, AGR%)
Figure 152 Antisense Therapeutics Limited: R&D, 2017-2021 (US$, AGR%)
List of Companies Profiled in the Report
Alnylam Pharmaceuticals, Inc.
Antisense Therapeutics Limited
Arrowhead Pharmaceuticals, Inc.
Bio-Path Holdings
Biogen
Geron Corporation (Geron)
GSK
Ionis Pharmaceuticals, Inc.
ProQR Therapeutics
Sarepta Therapeutics
Sterna Biologicals
List of Other Companies Mentioned in the Report
Akcea Therapeutics
Arbutus Biopharma,
Astellas Pharma Inc.
AstraZeneca
Bayer AG
Benitec BiopharmaLtd.
BioNTech
Creative Biolabs
CureVac AG
Dicerna Pharmaceuticals Inc.
Evox Therapeutics Ltd.
Gradalis Inc.
Moderna Inc.
Olix Pharmaceuticals
Quark Pharmaceuticals
Regulus Therapeutics
Rexahn Pharmaceutical Inc.
Sanofi-Genzyme
Silence Therapeutics
Sirnaomics Inc.
Synlogic Inc.
Tekmira Pharmaceuticals
List of Associations Mentioned in the Report
American Heart Association
American Journal of Infection Control(AJIC)
Biomedical Advanced Research and Development Authority (BARDA).
Center for Disease Control and Prevention (CDC)
Department of Health
European Medicines Agency (EMA)
Global Health Security Agenda (GHSA)
National Association for Biomedical Research
National Centre for Biotechnology Information
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health
U.S. Department of Health & Human Services
U.S. Food & Drug Administration
U.S. National Library of Medicine
World Health Organization
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
